This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

GTx Announces Presentation On Enobosarm’s Improvement In Physical Function In Cancer Patients With Both Low And Normal Testosterone Levels

GTx, Inc. (Nasdaq: GTXI) announced today that in a Phase IIb clinical study of enobosarm, there was significantly improved physical function after 16 weeks of treatment, compared to placebo, in both hypogonadal (low testosterone) and eugonadal (normal testosterone) subjects. The study met its primary endpoint of absolute change in total lean body mass (muscle) compared to placebo after 16 weeks of treatment. The data were reported by Adrian Dobs, M.D., M.H.S., professor of medicine and oncology, and Vice-Chair of the Department of Medicine, Faculty Development at The Johns Hopkins University Medical School, during the 2012 Annual Meeting of The Endocrine Society (ENDO 2012). Enobosarm is currently being evaluated in two pivotal Phase III clinical trials.

In the presentation, “Prevalence and Impact of Hypogonadism in Cancer Patients with Muscle Wasting in a Phase IIb Enobosarm Trial,” Dr. Dobs reported that enobosarm, a selective androgen receptor modulator (SARM), may play an important role in the management of cancer-related muscle wasting. When correlating baseline testosterone levels with weight loss, hypogonadal male subjects in GTx’s Phase IIb clinical study of enobosarm demonstrated greater weight loss than eugonadal males. Dr. Dobs noted that baseline physical function (stair climb power) of subjects in the study was higher among eugonadal versus hypogonadal males.

In the Phase IIb clinical study of enobosarm, 159 subjects were randomized to enobosarm or placebo for 16 weeks. The subjects were males greater than 45 years of age and postmenopausal females who had non-small cell lung cancer, colorectal cancer, non-Hodgkin’s lymphoma, chronic lymphocytic leukemia or breast cancer and experienced a 2% or greater weight loss during the 6 months prior to the study’s initiation. Of the 103 male subjects in the study, baseline testosterone levels were available for 93 men. 60% of the males were found to be hypogonadal at randomization, and the distribution of hypogonadism was similar across all forms of the cancers.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,472.37 +200.36 1.23%
S&P 500 1,951.36 +27.54 1.43%
NASDAQ 4,707.7750 +80.6910 1.74%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs